Clinical Research Directory

Inclusion Criteria: * Confirmed diagnosis of spontaneous, non-traumatic ICH. * 10 mL ≤ ICH ≤ 60 mL (confirmed via diagnostic and stability CT scans utilizing volumetric assessment) * Participants receiving anticoagulants are eligible upon reversal and stability within 24hrs after onset of ICH symptoms * Age ≥ 18 years * Able to receive first dose of test article ≤ 24h after onset of ICH symptoms * NIHSS score ≥ 2 at randomization or Glasgow Coma Scale ≥ 5 at randomization * Controlled blood pressure (systolic BP \< 180 mm Hg) at randomization. * Premorbid magnetic resonance spectroscopy (mRS) of 0-2 * Has adequate venous access * No planned surgical intervention except EVD * Written informed consent from the patient or legally authorized representative (LAR) Exclusion Criteria: * Unstable hematoma defined as \> 6 mL increase as compared to previous CT volume taken at least 6 hours apart within 24 hrs after onset of ICH symptoms. * Anticipated neurosurgical evacuation by open surgery or minimally invasive surgery with or without Alteplase (EVD allowed). * Uncontrolled temp \>38.5˚C at enrollment. * Signs of intracranial infection or emergence of a systemic infection * Is pregnant or lactating * Signs of liver and kidney chronic disease (i.e. creatinine \>2, bilirubin \> 3, receiving dialysis) * Non-reversible bleeding diathesis * Used any chronic immunosuppressants or chronic anti-inflammatory drugs (excluding low-dose aspirin), by any route of administration within the past 7 days. * Anticipated withdrawal of life-sustaining therapies within the first week after admission. * In the opinion of the investigator, patient has any contraindication to the planned study assessments. * In the opinion of the investigator, patient has a condition that could interfere with the proposed treatment or unacceptably increase the individual's risk by participating in the study. * Concomitant enrollment in another acute interventional study